<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306146</url>
  </required_header>
  <id_info>
    <org_study_id>CAD9303-101</org_study_id>
    <nct_id>NCT04306146</nct_id>
  </id_info>
  <brief_title>Study of CAD-9303 in Subjects With Schizophrenia</brief_title>
  <acronym>Affinity-1</acronym>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadent Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized,
      double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics
      of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining
      cohorts will be in participants with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized,
      double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics
      of CAD-9303. The effects of CAD-9303 will be explored on event-related potential (ERP), and
      on sensory and cognitive function. The first SAD cohort will be in healthy volunteer
      subjects. The remaining cohorts will be in participants with schizophrenia. Participants will
      meet specified eligibility criteria.

      Cohorts will be comprised of 8 subjects; 6 subjects will be administered CAD-9303, and 2
      subjects will be administered matching placebo.

      Potential subjects will undergo a screening period (up to 28 days), baseline assessments on
      Day -3, -2 and -1, and dosing on Day 1. A follow-up visit will occur 7 days after Day 1. The
      total duration of individual subject participation may be up to 5 weeks, depending on the
      duration of the screening period.

      The study will assess safety by adverse events, vital signs, laboratory parameters (including
      chemistry, hematology and urinalysis) and electroencephalogram (EEG); pharmacokinetics of
      CAD-9303; and exploratory efficacy measures effects on neurophysiological biomarkers,
      cognitive and negative symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">August 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety and tolerability of CAD-9303 in participants with schizophrenia and normal healthy volunteers (NHV)</measure>
    <time_frame>Day 1 through Day 7 Follow-up</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>CAD-9303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of CAD-9303 will be administered as a single dose. The initial dose will be 3 mg up to 1000 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be provided in capsules and administered as a single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAD-9303</intervention_name>
    <description>Capsules filled with CAD-9303 from 3 mg up to 1000 mg.</description>
    <arm_group_label>CAD-9303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Able to tolerate washout from antipsychotic medications for the duration of the
             planned cohort.

          -  Diagnosis of schizophrenia by Diagnostic and Statistical Manual of Mental Disorders
             (DSM-V) criteria with duration of illness &gt; 1 year since diagnosis.

          -  Clinical history of minimal, stable positive symptoms while under treatment with a
             stable psychotropic regimen.

        Key Exclusion Criteria:

          -  Abnormal findings on screening safety EEG or lifetime history of seizures or stroke.

          -  Meets current criteria of any psychiatric diagnosis other than schizophrenia, or
             lifetime history of any psychiatric diagnosis other than schizophrenia based upon the
             Mini International Neuropsychiatric Interview (MINI).

          -  Participants with moderate to severe extrapyramidal symptoms including tardive
             dyskinesia (Simpson-Angus Scale&gt;6, any Abnormal Involuntary Movement Scale (AIMS) Item
             1-7 &gt;2), and akathisia (Barnes Akathisia Rating Scale [BARS] Item 4 â‰¥1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cadent Therapeutics</last_name>
    <phone>617-949-5229</phone>
    <email>clinicaltrials@cadenttx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Voltattorni</last_name>
      <phone>562-304-1742</phone>
      <email>hannavoltattorni@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Wilkins</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>705</phone_ext>
      <email>lwilkins@hritrials.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

